What is the Safety of COVID-19 Vaccines in Immunocompromised Patients? Results from the European "Covid Vaccine Monitor" Active Surveillance Study.
Chiara BellittoNicoletta LuxiFrancesco CiccimarraLuca L'AbbateMonika RaethkeFlorence van HunselThomas LieberErik MulderFabio RiefoloFelipe VillalobosNicolas H ThurinFrancisco B MarquesKathryn MortonFergal O'ShaughnessySimona SonderlichováAndreea FarcasGiele-Eshuis JannekeMiriam C SturkenboomGianluca TrifiròPublished in: Drug safety (2024)
The overall safety profile of COVID-19 vaccines in immunocompromised people was favourable, with minor differences as compared to non-immunocompromised vaccinees. Participants mostly experienced mild ADRs, mainly reported after the first dose of Vaxzevria and Jcovden vaccines. Serious ADRs and AESI were rare.
Keyphrases
- coronavirus disease
- sars cov
- end stage renal disease
- respiratory failure
- newly diagnosed
- ejection fraction
- chronic kidney disease
- respiratory syndrome coronavirus
- peritoneal dialysis
- prognostic factors
- patient reported outcomes
- extracorporeal membrane oxygenation
- acute respiratory distress syndrome
- mechanical ventilation